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Fibroblast growth factor 21 (FGF21) is an effective regulator of glucose and lipidmetabolism. It
is mainly regulated by peroxisome proliferator activated receptors, and is widely associated
with cases of insulin resistance as obesity and type 2 diabetes (T2D). Our study aimed to
investigate thepotential effectsofomega-3 fattyacids, pioglitazone,andtheir combinationon
serum and liver FGF21 concentrations, and its hepatic gene expression in a ratmodel of T2D.
Wealso studied themodulating effects of these treatments onblood glucose, lipid profile, and
insulin resistance. T2Dwas induced inmale SpragueeDawley rats by combination of high fat
diet and low dose streptozotocin (35 mg/kg). Diabetic rats were treated with omega-3 fatty
acids (10%W/W diet), pioglitazone (20 mg/kg), and their combination for a period of 4 weeks.
Serum FGF21 concentration was significantly increased in diabetic rats. In contrast, hepatic
FGF21 concentration, and gene expressionwere significantly decreased. Omega-3 fatty acids,
pioglitazone,andtheir combinationsignificantlydecreasedserumFGF21.Omega-3 fattyacids
and combination therapy significantly decreased liver FGF21 concentration, with non-
significant changes in gene expression. On the other hand, pioglitazone significantly
increased hepatic FGF21 concentration and gene expression. Omega-3 fatty acids, pioglita-
zoneand their combinationsignificantly improved lipidprofile. Pioglitazoneandcombination
significantly decreased blood glucose levels and improved insulin resistance. In conclusion,
this study introduces the first evidence regarding the antidiabetic effects of omega-3 fatty
acids and pioglitazone combination, such effects are mediated through FGF21.
Copyright 2015, Mansoura University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Diabetes prevalence is increasing at an accelerating rate
approaching epidemic levels. Currently, there are 382 million81, þ20 1098969384.
om (L.A. Eissa), salmamo
ra University.
sity. Production and hosti
/licenses/by-nc-nd/4.0/).diabetic patients worldwide. In the Middle East and North
Africa, 1 in 10 adults have diabetes. Egypt is one of the top 10
countries in the number of people with diabetes (7.5million in
2013) and the number is expected to increase to 13.1million by
2035 [1]. Diabetes is characterized by hyperglycemia resultingssad2012@gmail.com (S.M. Eraky).
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Type 2 diabetes (T2D) is a heterogeneous, progressive disorder
initially characterized by glucose intolerance and compensa-
tory hyperinsulinemia, which in later stages progresses to
insulin resistance and impaired beta cell function [3].
Type 2 Diabetes, which accounts for 90e95% of diabetic
cases, is largely caused by social and lifestyle factors that can
be readily controlled [1,2]. Obesity leads to an increase in the
adipose tissue mass. This in turn triggers insulin resistance in
fat, skeletal muscle, and liver leading to T2D [4]. A medical
approach is not always sufficient for T2D management and
lifestyle modification should be considered.
Omega-3 fatty acids (u-3 fatty acids) have shown to possess
anti-inflammatory, and lipid lowering effects, suggesting a
possible beneficial effect in management of T2D and its
complications [5,6]. Several animal studies have shown that
administration of the u-3 fatty acids, eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA), prevented the devel-
opment of insulin resistance, obesity, and dyslipidemia [6e8].
These effects are mediated via interaction with peroxisome
proliferator-activated receptor a (PPAR-a) [9]. PPAR is a nuclear
receptor that plays important roles in adipocyte differentia-
tion, lipid and carbohydrate metabolism through transcrip-
tional regulation of different genes [10]. Other studies in T2D
patients and rat models of insulin resistance showed that u-3
fatty acids failed to reverse insulin resistance [6,11e14].
Pharmacological management of T2D aims to increase in-
sulin secretion or improve insulin sensitivity [15]. Pioglitazone
belongs to a class of drugs named thiazolidinediones, which
improve insulin sensitivity, lipid metabolism, and glucose
homeostasis through activation of PPAR-ˠ [16].
Fibroblast growth factor 21 (FGF21) is a recently identified
hormone that has an important role in glucose and lipid ho-
meostasis [17e19]. Rat FGF21 is a circulating protein derived
from a 208-amino acid mature protein encoded by the FGF21
gene located in chromosome 1 [20]. FGF 21 is detected in
plasma, so it is proposed to be secreted into circulation acting
as a true hormone. Its activity depends on binding to FGF re-
ceptors (FGFR) and a cofactor called b-Klotho, a trans-
membrane protein whose expression is stimulated during
development of preadipocytes to adipocytes [21]. The cofactor
b-Klotho is predominantly expressed in metabolic organs
including liver, white adipose tissue, and pancreas [22]. FGF21
has glucose-lowering effects through several mechanisms. It
stimulates glucose uptake in differentiated adipocytes via the
induction of glucose transporter-1 (GLUT1) [17,23,24]. Glucose
uptake induced by FGF21 is additive and independent of in-
sulin. It has also been reported that FGF21 might act on
glucagon metabolism, leading to decreased hepatic glucose
production, and increased liver glycogen [25]. Finally, FGF21
was shown to preserve b-cell function and survival [26].
Fibroblast growth factor 21 is produced by the liver and
white adipose tissue, under the influence of PPAR-a and PPAR-
g respectively [27,28]. It was reported that serum FGF21 con-
centration is significantly increased in case of hyper-
triglyceridemia, insulin resistance, and metabolic syndrome,
indicating a state of FGF21 resistance [29].
Peroxisome Proliferator Activated Receptor-g agonists
have been shown to lower blood glucose, total cholesterol, and
triglycerides concentrations and improve insulin resistance.Whether these effects are mediated via modulation of hepatic
FGF21 is still unclear. The aimof this study is to investigate the
potential anti-diabetic effects of combining a PPAR-a agonist
(u-3 fatty acids) and a PPAR-ˠ agonist (pioglitazone), and
whether these effects are mediated through modulation of
FGF21.2. Materials and methods
2.1. Drugs and chemicals
Omega-3 fish oil (containing EPA 180 mg and DHA 120 mg)
was purchased from Lifeplan (Lutterworth, Leicestershire,
England). Pioglitazone was supplied in the form of pharma-
ceutical product (Diabetin tablets, Uni Pharma co., Cairo,
Egypt). Streptozotocin (STZ) was purchased from Sigma-
eAldrich (St. Louis, Mo., USA). The feeding ingredients were
obtained from commercial sources and were of analytical
grades.
2.2. Animals
Fiftymale SpragueeDawley (SD) rats weighing 150e190 g were
allowed free access to food and tap water. Rats were kept
under standard conditions of temperature (22 ± 2+C) and
relative humidity (55 ± 5%) with 12-light/12-dark cycles. The
animal care and experiments described in this study were
complied with “ Research Ethics Committee” Faculty of
Pharmacy, Mansoura University, Egypt, in accordance with “
Principles of Laboratory Animal Care” (NIH publication No. 85-
23, revised 1985).
2.3. Induction of T2D
Experimental rats were maintained on a high fat diet (58% fat,
25% protein and 17% carbohydrate, as a percentage of total
kcal) ad libitum. The high-fat diet (HFD) was prepared and
composed as described by Srinivasan et al. (2005) [30]. After 1
month on high fat diet, experimental rats were injected
intraperitoneally with freshly prepared STZ (35 mg/kg body
weight) in 0.1 M citrate buffer (pH 4.5) after an overnight
fasting [30]. Control rats were injected with citrate buffer only.
Rats were continued on high fat diet until the end of study. To
overcome the hypoglycemia during the first 24 h after STZ
injection, diabetic rats were given 5% glucose solution instead
of drinking water. Only animals with persistent blood glucose
levels higher than 250 mg/dL for 7 days after STZ adminis-
tration were considered diabetic.
2.4. Experimental design
Animals were divided into:
1. Control group: maintained on normal pellet diet (3.15 kcal/
g), and intraperitoneally received single dose of citrate
buffer (0.1 M, pH 4.5).
2. Diabetic rats were divided into four groups as follows:
(i) Diabetes: in which diabetes was induced as previously
mentioned.
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(EPA and DHA) (10% of dietary intake of rats) [31].
(iii) Diabetes þ pio: diabetic rats treated with pioglitazone
(20 mg/kg body weight) [32].
(iv) Diabetes þ u-3 þ pio: diabetic rats treated with a
combination of both u-3 fatty acids (10% of dietary
intake of rats) and pioglitazone (20mg/kg bodyweight).
Treatments were administered by orogastric gavage, and
continued for 4 weeks.
2.5. Body weight
Body weights were monitored weekly during the study.
2.6. Collection of blood and tissue samples
At the end of the experiment, blood samples were withdrawn
from thiopental-anesthetized animals via retro-orbital punc-
ture and centrifuged at 1200  g for 10 min at 4 C for serum
preparation. Immediately after sacrificing the rats, dissection
was done for isolation of the liver. Sections of liver tissues
were collected, immediately immersed in liquid nitrogen, and
stored at 80 C for quantitative real-time reverse
transcription-polymerase chain reaction (RT-PCR) analysis.
0.5 g of liver tissues were homogenized in 5 ml ice-cold
phosphate buffer saline (0.02 M, pH 7.4) (10% w/v), centri-
fuged at 1500  g for 15 min at 4 C and frozen at 80 C until
further analysis of FGF21 by ELISA technique.
2.7. Analysis of serum total cholesterol, triglycerides,
and blood glucose
Serum triglycerides and total cholesterol concentrations were
measured using commercial kits (Spinreact, Spain). Blood
glucose was measured from tail vein using (ACCU-CHECK GO,
Roche Diagnostics, Mannheim, Germany) glucometer.
2.8. Measurement of fasting insulin concentration (mU/L)
Serum insulin concentration was measured by ELISA using
commercially available kit (MyBioSource, Inc., California,
USA).
2.9. Calculation of homeostasis model assessment of
insulin resistance (HOMA-IR) HOMA-IR was calculated
using the following formula
HOMA-IR¼ Fasting plasma glucose (mg/dl)  fasting insulin
(mU/L)/405.Table 1 e Primers sequence and direction.
Gene Direction Se
FGF21 Forward 50-ACAGATGA
Reverse 50-TAGAGGCT
GAPDH Forward 50-CCATCAAC
Reverse 50-CACGACATHOMA-IR, first described by Matthews et al. (1985), is a
method for estimating insulin sensitivity [33].2.10. Measurement of FGF21 concentration (pg/ml) using
ELISA
FGF21 concentration was measured in serum and liver ho-
mogenate by ELISA using a commercially available kit
(MyBioSource, Inc., California, USA).2.11. Gene expression of FGF21
 RNA isolation and c-DNA synthesis
Total RNA was isolated from liver tissues using easy-RED
total RNA extraction kit (iNtRON Biotechnology, Seongnam,
Korea) according to the manufacturer's protocol. RNA was
extracted with chloroform, followed by centrifugation at 4 C
to separate into aqueous and organic phases. RNA pellets
were recovered from the aqueous phase by isopropyl alcohol
precipitation and resuspended in nuclease-free water
(Thermo Fisher Scientific Inc.). A total of 1 mg of RNAwas used
for c-DNA synthesis using Maxima First Strand cDNA Syn-
thesis Kit for RT-qPCR (Thermo Fisher Scientific Inc.), ac-
cording to the manufacturer's instructions. The resulting c-
DNA products were stored at e 20 C.
 Real-time RT-PCR
Real-time RT-PCR was performed using Piko Real-PCR
System (Thermo Fisher Scientific Inc.), according to the
manufacturer's instructions. For a final reaction volume of
20 mL, the following reagents were added: 4 mL HOT FIREPol
EvaGreen qPCR Mix (Solis BioDyne, Tartu, Estonia), 1 mL each
of forward and reverse 10 mM primers, 12 mL nuclease free
water and 2 mL cDNA template. The primers used were
designed using PREMIER Biosoft, USA and the specific gene
sequences were obtained from Pubmed (Entrez Gene). Primer
sequence is described in Table 1.
The amplification was performed as follows: 1 cycle of
initial activation of DNA polymerase at 95 C for 15 min, then
repeated three-step cycling for 40 cycles: denaturation at 95 C
for 15 s, annealing at 60 C for 20 s and elongation at 72 C for
20 s.
mRNA levels were quantified by using comparative CT
method (2DDCTmethod). The data were normalized to GAPDH
RNA to account for differences in reverse transcriptase effi-
ciencies and the amount of template in the reactionmixtures.
The amplified samples were subjected to electrophoresis
through 2% agarose gel.quence Reference sequence
CGACCAGGACAC-30 NC_005100.4
TTGACACCCAGG-30
GACCCCTTCATT-30 NC_005103.4
ACTCAGCACCAGC-30
Fig. 1 e Effects of u-3 fatty acids (10% of diet), pioglitazone (20 mg/kg body weight) and their combination on body weight of
diabetic (D) animals. (A)Abar chart showingbodyweight at the endof the study. (B)A curve showing theweightsof animals in
eachgroupmonitoredweekly.Dataare representedasmeans±SEMof6e8animals/group. Statistically significantdifferences
are indicated as: *p < 0.05, ***p< 0.001, compared to D group. %%% p< 0.001, compared to Dþu-3 group. D:diabetes. Dþu-3:
diabetesþ u-3 fatty acids. Dþ pio: diabetesþ pioglitazone. Dþ u-3þ pio: diabetesþ u-3 fatty acidsþ pioglitazone.
Fig. 2 e Effects of u-3 fatty acids (10% of diet), pioglitazone (20 mg/kg body weight), and their combination on fasting blood
glucose (A) and HOMA-IR (B) of D animals. Data are represented as means ± SEM of 6e8 animals/group. Statistically
significant differences are indicated as: $$$ p < 0.001, compared to control group. *p < 0.05, ***p < 0.001, compared to D
group. %%% p < 0.001, compared to D þ u-3 group. D: diabetes D þ u-3: diabetes þ u-3 fatty acids. D þ pio:
diabetes þ pioglitazone D þ u-3 þ pio: diabetes þ u-3 fatty acids þ pioglitazone.
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Data are expressed asmeans ± standard error ofmean (SEM) in
each group. Statistical evaluations of the results, were carried
out by means of one way analysis of variance, followed by
Bonferronimultiple comparison test.Thecorrelational analysis
was performedusing PearsonCorrelation. Statistical testswere
performed using Statistical Package for the Social Sciences
(SPSS) version 13 (Chicago, IL, USA). Statistical significancewas
taken at P < 0.05. Graphing was carried out using Graphpad
Prism software (Graphpad Software Inc., San Diego, USA).4. Results
4.1. Effects of u-3 fatty acids, pioglitazone, and their
combination on body weight
Diabetic (D) group showed an increase in body weight fol-
lowed by acute weight loss after STZ injection (Fig. 1a). At the
end of study, pioglitazone monotherapy significantly
increased the body weight compared to diabetic (D) groupFig. 3 e Effects of u-3 fatty acids (10% of diet), pioglitazone (20 m
cholesterol (A) and serum triglycerides (B) of D animals. Data ar
Statistically significant differences are indicated as: $$$ p < 0.0
compared to D group. ### p < 0.001, compared to D þ pio. %%%
diabetes þ u-3 fatty acids. D þ pio: diabetes þ pioglitazone. D(p < 0.05). u-3 fatty acids treated group (Dþu-3) showed non-
significant change from diabetic (D) group. Combination
group (Dþu-3þpio) showed highly significant increase in the
body weight compared to diabetic (D) group (p < 0.001)
(Fig. 1b).
4.2. Effects of u-3 fatty acids, pioglitazone, and their
combination on fasting blood glucose concentration
u-3 fatty acids monotherapy significantly reduced fasting
blood glucose concentrations, compared to diabetic (D) rats
(p < 0.05), but remained higher than normal fasting blood
glucose concentration. Both pioglitazone and combination
therapy caused highly significant decrease in fasting blood
glucose concentration, compared to diabetic (D) group
(p < 0.001) (Fig. 2a).
4.3. Effects of u-3 fatty acids, pioglitazone, and their
combination on HOMA-IR
Diabetic (D) rats exhibited highly significant increase in
HOMA-IR compared to control group (p < 0.001), indicating a
state of insulin resistance. u-3 fatty acids monotherapyg/kg body weight) and their combination on serum total
e represented as means ± SEM of 6e8 animals/group.
01, compared to control group. ** p < 0.01, *** p < 0.001,
p < 0.001, compared to D þ u-3 group. D: diabetes. D þ u-3:
þ u-3 þ pio: diabetes þ u-3 fatty acids þ pioglitazone.
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group, suggesting absence of insulin-sensitizing effects. Pio-
glitazone and combination therapy showed a highly signifi-
cant decrease in HOMA-IR (p < 0.001) (Fig. 2b).
4.4. Effects of u-3 fatty acids, pioglitazone, and their
combination on serum total cholesterol (mg/dl) and serum
triglycerides (mg/dl)
Diabetic (D) rats showed a highly significant elevation in
serum total cholesterol and triglycerides concentrations,
compared to control group (p < 0.001). u-3 fatty acids, piogli-
tazone, and combination therapy caused a highly significant
reduction in serum total cholesterol and triglycerides,
compared to diabetic (D) group (p < 0.001). Interestingly,
combination therapy showed a highly significant decrease in
triglycerides concentration than either u-3 fatty acids or pio-
glitazone alone (p < 0.001) (Fig. 3a and b).
4.5. Effects of u-3 fatty acids, pioglitazone, and their
combination on serum FGF21 concentration (pg/ml) and
hepatic FGF21 concentration (pg/g liver tissue)
Serum FGF21 was increasedz 2-fold in diabetic (D) group,
compared to control group. u-3 fatty acids, pioglitazone, and
combination therapy significantly lowered serum FGF21,
compared to diabetic (D) group (p < 0.001) (Fig. 4a). As for he-
patic FGF21 concentration, diabetic (D) rats showed a highlyFig. 4 e Effects of u-3 fatty acids (10% of diet), pioglitazone (20 m
concentration (pg/ml) (A), hepatic FGF21 concentration (pg/g tis
animals/group. Statistically significant differences are indicated
compared to D group. ## p < 0.01, ### p < 0.001, compared to D
diabetes. D þ u-3: diabetes þ u-3 fatty acids. D þ pio: diabetes
acids þ pioglitazone.significant decrease, compared to control group (p < 0.01).
Pioglitazone monotherapy caused a highly significant in-
crease in hepatic FGF21 concentration (p < 0.001), while u-3
fatty acids therapy resulted in a highly significant decrease
whether administered alone or in combination with pioglita-
zone (p < 0.001) (Fig. 4b).
4.6. Effects of u 3 fatty acids, pioglitazone, and their
combination on hepatic FGF21 mRNA expression
Diabetic (D) group showedhighly significant decrease in FGF21
mRNA expression in liver (p < 0.001). Pioglitazone treated
group showed highly significant increase in hepatic FGF21
mRNA expression (p < 0.001), while both u-3 and combination
therapy showed non-significant changes from diabetic (D)
group (Fig. 5).
4.7. Correlation studies
Data in Table 2 show the correlational analysis of glucose,
HOMA-IR index, serum total cholesterol, serum triglycerides,
serum FGF21 concentration, hepatic FGF21 concentration and
FGF21 relative gene expression.
As shown in Fig. 6, serum FGF 21 showed significant posi-
tive correlation with blood glucose (r¼ 0.5, p < 0.01), HOMA-IR
(r¼ 0.390, p < 0.05).
As shown in Table 2, serum FGF 21 showed significant
positive correlation with serum total cholesterol (r¼ 0.695,g/kg body weight), and their combination on serum FGF21
sue) (B). Data are represented as means ± SEM of 6e8
as: $$$ p < 0.001, compared to control group. *** p < 0.001,
þ pio. %%% p < 0.001, compared to D þ u-3 group. D:
þ pioglitazone. D þ u-3 þ pio: diabetes þ u-3 fatty
Fig. 5 e Effects of u-3 fatty acids (10% of diet), pioglitazone (20 mg/kg body weight), and their combination on FGF21 mRNA
expression (A), gel electrophoresis (B). Data are represented as means ± SEM of 4 animals from each group. Statistically
significant differences are indicated as: $$$ p < 0.001, compared to control group. *** p < 0.001, compared to D group. D:
diabetes. D þ u-3: diabetes þ u-3 fatty acids. D þ pio: diabetes þ pioglitazone. D þ u-3 þ pio: diabetes þ u-3 fatty
acids þ pioglitazone.
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nificant positive correlationwas found between hepatic FGF21
concentration and itsmRNA expression (r¼ 0.448, p < 0.05). As
for HOMA-IR, it is positively correlated with serum total
cholesterol (r¼ 0.55, p < 0.01), serum triglycerides (r¼ 0.648,
p < 0.01) and blood glucose (r¼ 0.963, p < 0.01).5. Discussion
Combining life style changes with pharmacological therapy
has become mandatory for management of diseasesTable 2 e Correlational analysis of the studied parameters.
Blood
glucose
(mg/dl)
HOMA-IR
index
Serum total
cholesterol
(mg/dl)
Blood glucose (mg/dl) (r) 1 0.963** 0.567**
HOMA-IR index (r) 0.963** 1 0.550**
Serum total cholesterol
(mg/dl) (r)
0.567** 0.550** 1
Serum triglycerides
(mg/dl)(r)
0.724** 0.648** 0.851**
Serum FGF21 (pg/ml) (r) 0.500** 0.390* 0.695**
Liver FGF21 (pg/g.tissue) (r) 0.203 0.252 0.378*
*p < 0.05.
**p < 0.01.associated with metabolic disorders. Previous studies showed
the effectiveness of combining u-3 fatty acids with thiazoli-
dinediones, pioglitazone and rosiglitazone, inmice fed a high-
fat diet, possibly through induction of adiponectin [34].
In this study, we generated a rat model for T2D using a high-
fat diet followed by low dose STZ as previously described by
Srinivasan et al. (2005) [30]. T2D was confirmed by hyperglyce-
mia,mildhyperinsulinemia, andasignificant increase inHOMA-
IR index in diabetic rats. Our study is the first to investigate the
potential anti-diabetic effects of u-3 fatty acids and pioglitazone
combination through modulating FGF21. We have also corre-
lated FGF21 changes with different metabolic parameters.Serum
triglycerides
(mg/dl)
Serum
FGF21
(pg/ml)
FGF21 conc.
in liver (pg/gm
tissue)
Hepatic
FGF21 m-RNA
expression
0.724** 0.500** 0.203 0.435
0.648** 0.390* 0.252 0.345
0.851** 0.695** 0.378* 0.163
1 0.775** 0.304 0.222
0.775** 1 0.219 0.460*
0.304 0.219 1 0.448*
Fig. 6 e Correlation between serum FGF21 (pg/ml) and HOMA-IR (A) and blood glucose (B).
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combination exerted an additive improvement in insulin
sensitivity. This is in agreement with previous studies that
employed pioglitazone and rosiglitazone in combination with
u-3 fatty acids in rats fed a high-fat diet [34,35]. However, in
our study, rats were treated with much lower doses of pio-
glitazone in the combination therapy and managed to revert
insulin resistance.
The effect of u-3 fatty acids on insulin resistance has been
studied extensively leading to contradicting results. Consis-
tentwith our results, human studies suggested that none ofu-
3 fatty acids improve insulin sensitivity [36,37]. Similarly,
Gillam, et al. (2009) [11] found no beneficial effects of u-3 fatty
acids on insulin sensitivity in fa/fa Zucker rats, a rat model of
insulin resistance. In a rat model of T2D induced by high fat
diet, low dose STZ, Coppey et al. (2012) found that partial
replacement of saturated fats with menhaden oil, a natural
source of u-3 fatty acids failed to improve impaired glucose
utilization [38].
On the other hand, several murine models of insulin
resistance have shown beneficial effects of u-3 fatty acids in
prevention or reversal of insulin resistance. In an obesity
model of insulin resistance and fatty liver disease, dietary
intake of fish oil (8% wt/wt) had insulin sensitizing actions in
adipose tissue and liver [39]. In high sucrose diet-fed rats, 7%
fish oil supplementation reversed the insulin resistance [40].
However, the aforementioned studies are models of insulin
resistance or pre-diabetes state, none of them represent a
model of T2D, as we had in this study.
Pioglitazone caused significant reduction in blood glucose
concentrations as shown in various animal species by actingas insulin sensitizer [41]. u-3 fatty acids significantly
decreased fasting blood glucose, but still in levels higher than
normal ones. In a ratmodel of T2D, treatmentwithmenhaden
oil did not significantly change blood glucose levels, compared
to untreated diabetic rats [38].
Combining u-3 fatty acids with pioglitazone resulted in a
strong synergistic triglyceride-lowering effect. This is in
accordance with a previous study that showed an additive
effect with higher pioglitazone doses [34]. In the current study,
u-3 fatty acids significantly lowered total cholesterol and tri-
glycerides, compared to the untreated group. u-3 fatty acids
exert potential hypocholesterolemic effect through inhibition
of key enzymes related to cholesterol synthesis and transfer
such as 3-Hydroxy-3-methylglutaryl reductase and acyl-
CoA:cholesterol acyltransferase [42]. u-3 fatty acids selec-
tively lower triglycerides by increasing glucose flux to
glycogen, increasing mitochondrial b-oxidation, and
decreasing triglycerides synthesis, an effect that is mediated
partially by PPAR-a activation [43]. Pioglitazone was found to
significantly lower total cholesterol and triglycerides concen-
trations, compared to diabetic rats. PPAR-g activation controls
a variety of genes involved in different pathways of lipid
metabolism such as fatty acid uptake, fatty acid oxidation,
lipolysis, and lipoprotein assembly and transport [44e46].
Pioglitazone and combination therapy significantly
increased body weight, compared to diabetic group. Weight
gain is a major side effect of pioglitazone treatment, since
PPAR- g increases feeding by reducing leptin levels, a hormone
that regulates satiety center [43].
Several studies have reported the use of FGF21 as an
interesting external therapeutic agent for modulating insulin
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that FGF21 possesses beneficial effects on carbohydrate and
lipid metabolism, improving obesity and diabetes [17,47]. As
well, administration of recombinant FGF21 has been shown to
reverse hyperglycemia, hyperinsulinemia, and dyslipidemia
in ob/ob and diet-induced obese mice and in diabetic monkeys
[48e50].
Consistent with our results, many studies showed that
circulating FGF21 concentrations are elevated in insulin-
resistant states, such as glucose intolerance and T2D [51e54],
indicating a possible compensatory increase of FGF21 to over-
come insulin resistance. PPAR is a pivotal regulator of hepatic
FGF21 [27,55]. A recent study showed that FGF21 could be
regulated by PPAR-g activation in pancreatic islets of mice [56].
We investigated the possibility of regulating FGF21 con-
centrations in serum and liver and its gene expression byFig. 7 e Lipid-lowering effect of u-3 fatty acids and pioglitazone
effects of pioglitazone, mediated through FGF21.combining u-3 fatty acids as a PPAR-a agonist with pioglita-
zone as a PPAR-g agonist. Our results have shown that pio-
glitazone, u-3 fatty acids, and their combination significantly
decreased serum FGF21, compared to diabetic group, allevi-
ating the state of FGF21 resistance. Consistent with our re-
sults, Villarroya et al. (2014) showed that long-term dietary
treatment with u-3 fatty acids significantly decreased FGF21
protein levels in plasma, compared to high fat diet group [57].
A study on patients with T2D showed that addition of piogli-
tazone to exenatide therapy significantly reduced plasma
FGF21 levels [58].
Fibroblast growth factor 21 was previously thought to be a
hepatic hormone, preferentially expressed in the liver. How-
ever, it was reported that other tissues as adipose and muscle
tissue are important sources of FGF21 production [19,59e61].
In our study, serum FGF21 concentration was increased inas well as blood glucose lowering and insulin-sensitizing
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This discrepancy may be due to the contribution of adipose
tissue and other tissues in circulating FGF21 concentration.
Hepatic mRNA expression of FGF21 showed significant
decrease in diabetic group, which correlated positively to he-
patic FGF21 concentration. Consistent with our results, Oishi
and Tomita (2011) showed that pioglitazone significantly
increased hepatic FGF21 mRNA expression in mouse liver and
in cultured hepatocytes [62].
In agreement with our results, recent studies of Jin et al.
(2014) and Lin et al. (2014) found that circulating FGF21 was
significantly and positively correlated with fasting blood
glucose concentration and HOMA-IR [63,64]. Also, we have
found a significant positive correlation between serum FGF21
and both serum total cholesterol and triglycerides, which is
consistent with Matuszek et al. (2010) [59].6. Conclusion
Combining PPAR-a agonists, as u-3 fatty acids, with PPAR-ˠ
agonists, as pioglitazone, showed potential effects in lowering
blood glucose concentration, improving lipid profile and in-
sulin resistance. Such effects are mediated through modula-
tion of FGF21 expression (Fig. 7).r e f e r e n c e s
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